• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Scientific Publications by FDA Staff

  • Print
  • Share
  • E-mail
-

Search Publications



Fields



Centers











Starting Date


Ending Date


Order by

Entry Details

Am Heart J 2012 Oct;164(4):481-92

Pediatric cardiovascular safety: Challenges in drug and device development and clinical application.

Bates KE, Vetter VL, Li JS, Cummins S, Aguel F, Almond C, Dubin AM, Elia J, Finkle J, Hausner EA, Joseph F, Karkowsky AM, Killeen M, Lemacks J, Mathis L, McMahon AW, Pinnow E, Rodriguez I, Stockbridge NL, Stockwell M, Tassinari M, Krucoff MW

Abstract

Development of pediatric medications and devices is complicated by differences in pediatric physiology and pathophysiology (both compared with adults and within the pediatric age range), small patient populations, and practical and ethical challenges to designing clinical trials. This article summarizes the discussions that occurred at a Cardiac Safety Research Consortium-sponsored Think Tank convened on December 10, 2010, where members from academia, industry, and regulatory agencies discussed important issues regarding pediatric cardiovascular safety of medications and cardiovascular devices. Pediatric drug and device development may use adult data but often requires additional preclinical and clinical testing to characterize effects on cardiac function and development. Challenges in preclinical trials include identifying appropriate animal models, clinically relevant efficacy end points, and methods to monitor cardiovascular safety. Pediatric clinical trials have different ethical concerns from adult trials, including consideration of the subjects' families. Clinical trial design in pediatrics should assess risks and benefits as well as incorporate input from families. Postmarketing surveillance, mandated by federal law, plays an important role in both drug and device safety assessment and becomes crucial in the pediatric population because of the limitations of premarketing pediatric studies. Solutions for this wide array of issues will require collaboration between academia, industry, and government as well as creativity in pediatric study design. Formation of various epidemiologic tools including registries to describe outcomes of pediatric cardiac disease and its treatment as well as cardiac effects of noncardiovascular medications, should inform preclinical and clinical development and improve benefit-risk assessments for the patients. The discussions in this article summarize areas of emerging consensus and other areas in which consensus remains elusive and provide suggestions for additional research to further our knowledge and understanding of this topic.


Category: Journal Article
PubMed ID: #23067905 DOI: 10.1016/j.ahj.2012.07.019
Includes FDA Authors from Scientific Area(s): Drugs Medical Devices Women's Health
Entry Created: 2012-12-03 Entry Last Modified: 2013-10-17
Feedback
-
-